|
| | Trial | , inclusion criteria | Dose (dose per fraction) | Outcome |
|
| Early hypofractionation trials |
Lukka et al. [44] | 936
GS 6–10 | 52.5 Gy (2.625 Gy)
66 Gy (2 Gy) | 40% versus 43% 5-year freedom from biochemical failure |
|
Yeoh et al. [45] | 217 | 55 Gy (2.75 Gy)
64 Gy (2 Gy) | 53% versus 34% 7-year freedom from biochemical failure |
|
| Modern superiority trials |
Hoffman et al. [47] | 204
99% low-intermediate risk | 72 Gy (2.4 Gy)
75.6 Gy (1.8 Gy) | 96% versus 92% 5-year freedom from biochemical failure |
|
Pollack et al. [49] | 303
GS 6+ | 70.2 Gy (2.7 Gy)
78 Gy (2.17 Gy) | 23% versus 21% 5-year biochemical or clinical disease failure |
|
Arcangeli et al. [48] | 168
GS 7+ | 62 Gy (3.1 Gy)
80 Gy (2 Gy) | 85% versus 79% 5-year freedom from biochemical failure |
|
| Modern noninferiority trials |
Dearnaley et al. [46] | 457 | 57 Gy (3 Gy)
60 Gy (3 Gy)
74 Gy (2 Gy) | Similar GU and GI toxicity ≥ grade 2 (<5%) |
| Incrocci [52] | 820
Intermediate-high risk | 64.6 Gy (3.4 Gy)
78 Gy (2 Gy) | Worse GI toxicity ≥ grade 2, similar GU toxicity |
| RTOG 0415 [51] | 1101
Low risk | 70 Gy (2.5 Gy)
73.8 Gy (1.8 Gy) | Noninferior biochemical recurrence and overall survival, similar toxicity |
| PROFIT [53] | Intermediate risk | 60 Gy (3 Gy)
78 Gy (2 Gy) | Pending |
|
